Head-to-head evidence
Burixafor (TG-0054) vs GPC-100
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CXCR4 · full Multiple Myeloma pipeline
Burixafor (TG-0054)
Developed by GPCR Therapeutics, Inc.
NCT01018979 · Phase 2 · completed
Although this study assigned patients to two dose levels, it had no placebo or active-comparator arm and was fully open-label (no masking), so there was no control against which to judge the drug's effect. Only 19 patients were treated, and most (13 of 19) dropped out before completing collection because their stem cell counts never rose high enough, leaving just 4 and 3 patients per dose group who even underwent apheresis for the primary mobilization-success endpoint. With no control arm and such a small, high-dropout sample, this is uncontrolled, exploratory evidence rather than a definitive efficacy trial.
GPC-100
Developed by GPCR Therapeutics, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Burixafor (TG-0054)'s landscape · GPC-100's landscape